[go: up one dir, main page]

WO2013053008A3 - Molecules which bind clec9a - Google Patents

Molecules which bind clec9a Download PDF

Info

Publication number
WO2013053008A3
WO2013053008A3 PCT/AU2012/001233 AU2012001233W WO2013053008A3 WO 2013053008 A3 WO2013053008 A3 WO 2013053008A3 AU 2012001233 W AU2012001233 W AU 2012001233W WO 2013053008 A3 WO2013053008 A3 WO 2013053008A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
methods
modulating
dendritic
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AU2012/001233
Other languages
French (fr)
Other versions
WO2013053008A2 (en
Inventor
Peter Malcolm Colman
Ross Leon Coppel
Peter Edward Czabotar
Mireille Hanna Lahoud
Nicos Anthony Nicola
Antonia Natalie POLICHENI
Kenneth Douglas Shortman
Kirsteen McInnes TULLETT
Jian-Guo Zhang
Jacob Baum
Wilson Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Walter and Eliza Hall Institute of Medical Research
Original Assignee
Walter and Eliza Hall Institute of Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Walter and Eliza Hall Institute of Medical Research filed Critical Walter and Eliza Hall Institute of Medical Research
Publication of WO2013053008A2 publication Critical patent/WO2013053008A2/en
Publication of WO2013053008A3 publication Critical patent/WO2013053008A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to the identification of molecules which bind the dendritic cell marker known as Clec9A. The present invention provides new compounds for targeting therapeutic agents such as antigens to dendritic cells. Also provided are methods of modulating a humoral and/or T-cell mediated immune response to the antigen, methods of delivery of a cytotoxic agent to dendritic cells thereof involved in diseased states, methods of modulating the uptake and/or clearance of cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof, and methods of modulating antigen recognition, processing and/or presentation, as well as immune responses to material derived from cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof.
PCT/AU2012/001233 2011-10-14 2012-10-12 Molecules which bind clec9a Ceased WO2013053008A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161547632P 2011-10-14 2011-10-14
US61/547,632 2011-10-14
US201261596083P 2012-02-07 2012-02-07
US201261596081P 2012-02-07 2012-02-07
US61/596,081 2012-02-07
US61/596,083 2012-02-07

Publications (2)

Publication Number Publication Date
WO2013053008A2 WO2013053008A2 (en) 2013-04-18
WO2013053008A3 true WO2013053008A3 (en) 2013-06-20

Family

ID=48082599

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2012/001233 Ceased WO2013053008A2 (en) 2011-10-14 2012-10-12 Molecules which bind clec9a

Country Status (1)

Country Link
WO (1) WO2013053008A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
ES2981745T3 (en) 2016-02-05 2024-10-10 Orionis Biosciences BV Bispecific signaling agents and their uses
WO2018201017A1 (en) * 2017-04-27 2018-11-01 Washington University Dendritic cell targeted adenovirus for vaccination
CA3069994A1 (en) 2017-08-09 2019-02-14 Orionis Biosciences Inc. Pd-1 and pd-l1 binding agents
CN117924493A (en) 2017-08-09 2024-04-26 奥里尼斯生物科学有限公司 CLEC9A binding agents and uses thereof
US11566072B2 (en) 2017-08-09 2023-01-31 Orionis Biosciences, Inc. CD8 binding agents
KR20200130339A (en) 2018-03-06 2020-11-18 프레시전 인코포레이티드 Human papillomavirus vaccine and uses thereof
WO2020041720A1 (en) 2018-08-24 2020-02-27 Codiak Biosciences, Inc. Extracellular vesicles targeting dendritic cells and uses thereof
WO2020097350A1 (en) 2018-11-08 2020-05-14 Orionis Biosciences, Inc. Modulation of dendritic cell lineages
WO2020191361A2 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Extracellular vesicles for vaccine delivery
EP3941607A1 (en) 2019-03-21 2022-01-26 Codiak BioSciences, Inc. Process for preparing extracellular vesicles
CN120590542A (en) 2019-03-28 2025-09-05 奥里尼斯生物科学股份有限公司 CLEC9A-based chimeric protein complex
US20220323519A1 (en) 2019-04-17 2022-10-13 Codiak Biosciences, Inc. Compositions of exosomes and aav
EP4117717A1 (en) 2020-03-13 2023-01-18 Codiak BioSciences, Inc. Extracellular vesicles for treating neurological disorders
WO2021189047A2 (en) 2020-03-20 2021-09-23 Codiak Biosciences, Inc. Extracellular vesicles for therapy
CN112724199B (en) * 2020-12-30 2023-01-24 郑州大学 Polypeptide with affinity Clec9a and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010108215A1 (en) * 2009-03-23 2010-09-30 The Walter And Eliza Hall Institute Of Medical Research Compounds and methods for modulating an immune response

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010108215A1 (en) * 2009-03-23 2010-09-30 The Walter And Eliza Hall Institute Of Medical Research Compounds and methods for modulating an immune response

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AHRENS, S. ET AL.: "F-Actin Is an Evolutionarily Conserved Damage-Associated Molecular Pattern Recognized by DNGR-1, a Receptor for Dead Cells", IMMUNITY, vol. 36, no. ISSUE, April 2012 (2012-04-01), pages 635 - 645, XP002693451 *
HOWARD, T. ET AL.: "The 47-kD Protein Increased in Neutrophil Actin Dysfunction With 47- and 89-kD Protein Abnormalities Is Lymphocyte-Specific Protein", BLOOD, vol. 83, no. 1, January 1994 (1994-01-01), pages 231 - 241 *
NESTOR, M. W. ET AL.: "The Actin Binding Domain of betal-Spectrin Regulates the Morphological and Functional Dynamics of Dendritic Spines", PLOS ONE, vol. 6, no. ISS. 1, January 2011 (2011-01-01), pages E16197, XP055071897 *
SANCHO, D. ET AL.: "Identification of a dendritic cell receptor that couples sensing of necrosis to immunity", NATURE, vol. 458, no. 7240, April 2009 (2009-04-01), pages 899 - 903, XP002693445 *
ZHANG, J.-G. ET AL.: "The Dendertic Cell Receptor Clec9A Binds Damaged Cells via Exposed Actin Filaments", IMMUNITY, vol. 36, no. ISS. 4, April 2012 (2012-04-01), pages 646 - 657, XP002693452 *

Also Published As

Publication number Publication date
WO2013053008A2 (en) 2013-04-18

Similar Documents

Publication Publication Date Title
WO2013053008A3 (en) Molecules which bind clec9a
MX378807B (en) CD20-BINDING IMMUNOTOXINS FOR INDUCING CELLULAR INTERNALIZATION AND METHODS USING THEM.
WO2012159754A3 (en) Individualized vaccines for cancer
EP4406612A8 (en) Anti-cd70 antibody drug conjugates
PH12015501092A1 (en) Anti-ceacam5 antibodies and uses thereof
EA201790862A1 (en) RELATING ERYTHROCYTES THERAPEUTIC TOOLS
WO2013120012A3 (en) Cdim binding proteins and uses thereof
AR093377A1 (en) ANTI-NOTCH ANTIBODIES AND ANTIBODY-FARMACO CONJUGATES
WO2013142324A8 (en) Neutralizing antibodies to hiv-1 and their use
MY174259A (en) Antigen binding protein and its use as addressing product for the treatment of cancer
MX363307B (en) Antigen delivery platforms.
MX2014015830A (en) Lsr antibodies, and uses thereof for treatment of cancer.
WO2014011901A3 (en) Methods and compositions for delivery of biologics
MX392812B (en) CATIONIC TRIALKYL LIPIDS AND METHODS OF USING THEM.
PH12014500866A1 (en) Immunobinders directed against tnf
UA118332C2 (en) Cs27l antigen binding proteins
WO2011032161A8 (en) Vaccines directed to langerhans cells
EP4509189A3 (en) Anti-fcrn antibodies
WO2013040142A3 (en) Bioinformatic processes for determination of peptide binding
MX384422B (en) Vector that jointly expresses vaccines and co-stimulatory molecules
CA2872308A1 (en) Novel ha binding agents
WO2013177593A3 (en) Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies
WO2012047267A3 (en) Polyvalent immunogen
MX350096B (en) Vacuum -assisted preservation of biological products, in particular of vaccines.
MA37749B1 (en) Vaccines against bluetongue and African horse sickness virus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12840003

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12840003

Country of ref document: EP

Kind code of ref document: A2